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The 2 pathways of ‘adenoma-carcinoma sequence’ (ACS)
(Morson, 1974; Vogelstein et al, 1988; Fearon and Jones, 1992)
and ‘de novo’ carcinogenesis (Shamsuddin et al, 1985; Kuramoto
and Oohara, 1988; Shimoda et al, 1989; Rembacken et al, 2000)
have been advocated as the representative mechanisms leading to
the sporadic colorectal carcinoma. In the former, carcinoma is
thought to arise from the pre-existing adenoma, and in the latter it
is thought to develop directly from the non-neoplastic colorectal
epithelia. Although the multistage progressive processes in the
ACS have been elucidated using various oncogenes and tumour
suppressor genes (Vogelstein et al, 1988; Fearon and Jones, 1992),
the scenario of ‘de novo’ carcinogenesis has little genetic evidence
to establish this pathway. To date, it has been suggested that p53
has a more important role in the development of ‘de novo’ carci-
noma than K-ras, which frequently involves in the ACS theory
(Yamagata et al, 1994; Minamoto et al, 1994; Mueller et al, 1996).
However, if some mucosal change in the normal appearing
colorectal mucosa can not be identified as a candidate for prema-
lignant lesion, it may be impossible to investigate the ‘de novo’
carcinoma pathway. 
Glycogen phosphorylase (GP) (EC 2.4.1.1) plays a central role
in the mobilization of carbohydrate reserves in a wide variety of
organs and tissues, and is one of the most carefully investigated
enzymes in history (Cori and Cori, 1936; Krebs and Fisher, 1956;
Davis et al, 1967; Newgard et al, 1989). Mammalian GPs are
found in 3 major isoforms, i.e. muscle, liver and brain (BGP), that
can be distinguished by functional and structural properties as well
as by the tissues in which they are predominantly expressed
(Shimada et al, 1986; Newgard et al, 1989). cDNAs encoding the 3
human GP isoforms have been cloned and sequenced (Nakano 
et al, 1986; Newgard et al, 1988). The physiological role of BGP is
poorly understood, but it is generally thought to induce an emer-
gency glucose supply during a stressful and ischaemic period
including neoplastic state. In addition, it has been suggested that
the major isoform of GP found in fetal and tumour tissues is BGP,
and BGP has been demonstrated to be identical with fetal-type GP
(Sato et al, 1972; Shimada et al, 1987, 1999; Gelinas et al, 1989). 
We have recently demonstrated BGP expression common in
the colorectal carcinomas, increasing in the ACS multisteps, and
frequent in the transitional mucosa of colorectal carcinoma
without any adenoma component (Tashima et al, 2000). The BGP
visualized by immunohistochemistry was commonly present in
colorectal carcinoma (80/96: 83.3%). The expression of this mole-
cule during ACS showed excellent correlation with the increased
dysplasia and was found prior to p53 expression, whereas no BGP
expression was seen in the normal human large intestine remote
from the cancer foci. Positive BGP staining in colorectal mucosa
(BGP focus) both in the proliferating zone and epithelial cells was
observed mainly around pure carcinomas without any adenoma
component. These results indicate that the BGP focus may
contribute to the carcinogenesis of the ‘de novo’ carcinoma. Adja-
cent mucosa around existing carcinoma, the so-called ‘transitional
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distinct entity which is indicative of premalignant changes such as
high proliferative activity (Wang et al, 1992) or K-ras mutation
(Zhang et al, 1998) in the crypt stem cell. These observations
support the contention that a malignant field change exists in
transitional mucosa adjacent to a colorectal carcinoma. 
In the present study, the BGP foci are further investigated using
proliferating analysis and genetic alterations, and we discuss
these BGP foci as a potentially precancerous lesion of ‘de novo’
carcinoma. 
MATERIALS AND METHODS 
Tissues 
96 human specimens were surgically resected from patients with
colorectal carcinoma. Tissues were fixed in 10% buffered formalin
for 4 days, sliced approximately 5 cm in length, embedded in
paraffin, and cut into serial 5 sections for histological and
immunohistochemical examinations. The first section in those was
stained with haematoxylin and eosin, and examined under a light
microscope. 
To investigate the ‘de novo’ carcinogenesis, 17 colorectal carci-
nomas with invasion into the submucosa or superficial muscularis
propria (upper one-third of muscularis propria) without any
adenoma component expressing both immunoreactive p53 and
BGP protein were selected from the 96 resected specimens. The
mean size of the seventeen carcinoma were 2.6 ± 0.9 cm (mean ±
SD) in diameter. All patients were Japanese. Age ranged from 38
to 81 (62 ± 12: mean ± SD), and the ratio of male to female was
9:8. 3 serial sections of 3 mm for PCNA, p53 and BGP staining
each, and 5 to 8 mm were prepared for further examination of 
K-ras and p53 mutation. 
Antibodies 
Antibody against human BGP was raised as previously reported
by Ignacio et al (1990) with modification. Briefly, a synthesized
13-residue peptide (CDLQIPPPNIPRD) corresponding cystein
coupled to the 12 carboxyterminal residues of BGP was chosen 
for immunogen, which had no significant homology with other
proteins including human liver and muscle-type GP using GENE
WORKS homology search. The N-terminal cysteine of the peptide
was coupled with activated keyhole limpet haemocyanin (KLH)
(PIERCE, Illinois, USA). Adult rabbits were immunized by 4
subcutaneous injections at one week intervals, with 100 mg of the
KLH-peptide with Freund’s complete or incomplete adjuvant. One
week after the last injection the same amount of KLH-peptide was
injected subcutaneously as a booster, and one week later blood
samples were collected from the jugular vein. The immunoglob-
ulin G (IgG) fractions of pooled antisera (approximately 100 ml)
were precipitated by adding saturated (NH4)2SO4 (50% saturation),
dissolved in 100 ml of PBS and dialysed extensively in the same
buffer. A part of this IgG fraction (2 ml) was then applied to a
column of BGP-coupled Sepharose (1 mg of the BGP peptide 
was coupled with 1 ml of Hi Trap NHS-activated Sepharose)
(Pharmacia Biotech, Uppsala, Sweden) at a flow rate of 0.5 ml
min–1 at room temperature. The column was washed successively
with buffer A (0.5 M ethanolamine, 0.5 M NaCl, pH 8.3) and
buffer B (0.1 M acetate buffer, 0.5 M NaCl, pH 4.0). Then the 
antibodies bound in the column were eluted with 0.1 M glycine-
HCl buffer, pH 2.5, containing 1 M NaCl. Fractions containing
antibodies, which were detected by measuring the absorbance at
280 mn, were collected, neutralized immediately with 1 M
NaOH, and dialysed against PBS buffer. 
Anti-p53 Ab (BP53.12) and anti-proliferating cell nuclear
antigen (PCNA) Ab (PC-10) was purchased from ZYMED
Laboratory Inc (San Francisco, CA, USA) and Medac (Hamburg,
Germany), respectively. 
Immunohistochemistry 
The ABC Elite kits (Vector Laboratories, Inc. Burlingame, CA,
USA) for rabbit IgG (anti-BGP) and mouse IgG (anti-p53 and
anti-PCNA) were used. Sections of formalin-fixed and paraffin-
embedded tissue (3 mm thick) were deparaffinized and hydrated
through xylene and graded ethanols. Sections were incubated with
normal horse serum for 30 min following the blocking of endoge-
nous peroxidase activity with 0.3% H2O2 in methanol for 30 min,
incubated overnight at 4˚C with optimally diluted (see below)
primary Ab, and subsequently incubated with biotinylated anti-
rabbit and -mouse IgG Ab and avidin-biotin peroxidase complex
for 30 min at room temperature. They were washed in 10 mM 
PBS (pH 7.2) between each incubation step. The sites of peroxi-
dase activity were visualized by the diaminobenzidine method.
Sections were counter stained with haematoxylin for microscopic
examination. In p53 staining, heat antigen retrieval was used (Shi
et al, 1991). Sections were immersed in 1 l of citrate buffer (2.1 g
citric acid in 1 l distilled water: pH 6.0 with 2 M NaOH) and
boiled 30 min before the immunohistochemical procedure. The
working dilutions of the primary antibodies employed in this study
were 1 mgm l –1 of the affinity purified anti-BGP Ab, and 1:800
dilution for PC-10 (anti-PCNA Ab). BP53.12 (anti-p53 Ab) predi-
luted by the manufacturer was directly applied without additional
dilution. As a negative control, non-immunized rabbit and mouse
IgG were used instead of the primary Ab. 
PCNA labelling index 
The PCNA labelling index of colorectal carcinoma was deter-
mined as the percentage of immunoreactive nuclei in 1000 cells. In
colorectal mucosa, PCNA labelling index was expressed as the
percentage of positive cells in a longitudinally sectioned colorectal
tubule. Calculated data were expressed as mean ± SD. 
Microdissection 
Based upon BGP staining of 3 mm section, each part of the carci-
noma with positive BGP staining, BGP focus, and BGP negative
colorectal mucosa were collected in microtubes from all of the 5 
8 mm serial sections using needles (0.41 mm outer diameter). To
eliminate the contamination of the carcinoma cells, the BGP nega-
tive colorectal mucosa was collected first, subsequently the BGP
foci, and at last the carcinoma part using new needles. Genomic
DNA was extracted from tissues by proteinase K digestion and
phenol/chloroform extraction (Sambrook et al, 1989), with minor
modifications. 
Primers 
Oligonucleotides were synthesized as primers for PCR based on
the published p53 gene sequence for each region flanking the
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sequences for each primer were as follows; EX-05f: 5¢-TCTGTCT-
CCCTTCCTCTTCCT-3¢, EX-05r: 5¢-TCTCCAGCCCCAGCT-
GCT-3¢, EX-06f: 5¢-TGATTCCTCACTGATTGCTCT-3¢, EX-
F05r:F-5¢-TCTCCAGCCCCAGCTGCT-3¢,EX-06f:5¢-TGATCCT
CACTGATTGCTCT-3¢, EX-06r: 5¢-GAGACCCCAG-TTGCCA-
AACC-3¢, EX-F06r: F-5¢-GAGACCCCAGTTGCCAAACC-3¢,
EX-07f: 5¢-TCTTGGGCCTGTGTTATCTC3¢, EX-07: 5¢-
AGGGTGGCAAGTGGCTCC-3¢, EX-F07r: F-5¢-AGGG
TGGCAAGTGGCTCC-3¢, EX-08f: 5¢GCTTCTCTTTTCCTATC-
CTGA-3¢, EX-08r: 5¢-CGCTTCTTGTCCTGCTTGC-3¢, and EX-
F08r: F-5¢-CGCTTCTTGTCCTGCTTGC-3¢. The number in each
designation indicates the region of the exon of the p53 gene
subjected to examination by polymerase chain reaction-single
strand conformation polymorphism (PCR-SSCP) or fluorescence-
based PCR-SSCP (PCR-FSSCP) analysis. ‘f’ and ‘r’ indicate
forward and reverse primers respectively, for each region. The
reverse primers were labeled at their 5¢ ends with fluorescein
derivatives by the Fluore prime method (Pharmacia Biotech,
Uppsala, Sweden). ‘F’ indicates carboxyfluorescein linked to the 5¢-
nucleotide via a linker and phosphate. 
We used synthesized oligonucleotides, K1203f: 5¢-GTACTG-
GTGGAGTATTTGATAGT-3¢ and K1204r: 5¢CATGAAAATG-
GTCAGAGAAACC-3¢, as primers for codon 12 of K-ras
PCR-SSCP analysis. ‘f’ and ‘r’ indicate forward and reverse
primers respectively. 
PCR-SSCP analysis 
The target sequences were amplified by PCR in 50 ml of solution
containing 1 mM concentrations of the primers, 100 mM concen-
trations of dATP, dCTP, dGTP and TTP, 100 ng of human genomic
DNA, and 0.125 units of Amplitaq (Perkin-Elmer Cetus, Norwalk,
CT, USA) in the buffer recommended for the enzyme. All PCR
reactions were performed in a Robo-Cycler™ (STRATAGENE,
La Jolla, CA, USA) over 40 cycles. Each reaction cycle included
denaturation at 95˚C for 1 min, primer annealing at 56˚C for 1.5
min, and primer extension at 72˚C for 1.5 min. 10 ml of PCR prod-
ucts were diluted 2-fold by a buffer consisting of 20 mM EDTA,
96% formamide, 0.05% bromophenol blue, and 0.05% xylene
cyanol and heated at 95˚C for 5 min, and then placed on ice for 5
min. Then 10 ml of this solution was applied to each lane of a 7.5%
neutral small polyacrylamide gel (8 cm ´ 9 cm). Electrophoresis
was performed at 5 V cm–1 for 3 to 4 h, depending on the length of
the amplified nucleotide. The gel was stained with ethidium
bromide and visualized under UV light. 
PCR-FSSCP analysis 
100 ng of genomic DNA was amplified in a total volume of 50 ml
in the buffer recommended by Perkin-Elmer Cetus as described
above, using the reverse primers labelled at 5¢ ends with fluores-
cein. The PCR products were diluted 50-fold by a stop solution
(Pharmacia Biotech, Uppsala, Sweden), heated at 95˚C for 5 min,
and then placed on ice for 5 min. Then 4 ml of this solution was
applied to each lane of the FSSCP gel fitted to an ALF II auto-
mated DNA sequencer (Pharmacia Biotech, Uppsala, Sweden).
The FSSCP gels used 7% polyacrylamide gel containing 5% glyc-
erol. Electrophoresis was performed at 30 W for 3 to 4 h,
depending on the length of the amplified nucleotide. The
temperature of the gel was kept at 25˚C with a built-in water jacket
connected to an external thermostat-regulated water circulation
system. 
Cloning and DNA sequencing of PCR products 
PCR using EX-05f/EX-05r, EX-06f/EX-06r and EX-07f/EX-07r
as primer pairs was performed as described above. The Amplified
fragments were cloned in the TA cloning site of the pCR II™
cloning vector (Invitrogen, USA) using T4 DNA ligase (Takara
Shuzo, Tokyo, Japan). Approximately 20 recombinant colonies
were selected and cultured in TB (Terrific Broth, USA) medium.
These recombinant clones were amplified using EX-05f/EX-F05r,
EX-06f/EX-F06r or EX-07f/EX-F07r primer pairs, and PCR prod-
ucts were then analysed by FSSCP techniques. Sequences analysis
of these PCR-amplified fragments in the cloning vector was
performed using the ALF II automated DNA sequencer analyser
with M13 primers. 
Statistics 
Statistical analyses were performed using Student’s t-test. 
RESULTS 
BGP and p53 protein expression in colorectal
carcinoma, transitional mucosa and normal mucosa 
The 17 carcinomas included 12 colonic carcinomas and 5 rectal
carcinomas. The reactivity of colonic carcinoma against anti-BGP
Ab and p53 is shown in Figures 1A and 1B. The positive reactivity
of BGP and p53 was observed in the cytoplasm and nucleus of
cancer cells, respectively. Although no immunohistochemical
staining of BGP or p53 was observed in normal colonic and rectal
mucosa remote from the cancer foci even in their proliferating
zone, the transitional mucosa of the carcinomas in all of the 17
cases contained localized BGP foci sporadically (Figure 1A). The
BGP foci adjacent to the carcinomas is shown in Figures 2A and 2B.
The BGP staining pattern of the colorectal tubules in the BGP foci
were observed typically in the proliferating cell zone, but some-
times it also expanded to the superficial epithelial cells. The mean
diameter of the investigated BGP foci and distance from the main
tumours were 2.8 ± 1.7 mm and 23.7 ± 19.6 mm (mean ± SD),
respectively. The mean number of the BGP foci in each immuno-
histochemical section of the 17 carcinomas was 3.9 ± 2.7 (mean ±
SD). No p53 protein overexpression, however, was detected in the
BGP foci when using a heat antigen retrieval method (Figure 1B).
Similar histologic characteristics to transitional mucosa such as
crypt distortion and basal cell hyperplasia was observed in BGP
foci in comparison with the BGP negative normal mucosa. 
Proliferating state in the BGP foci 
The proliferative compartment in the BGP-negative normal
colorectal mucosa were restricted to the lower layer (Figures 3C
and 3D). In the BGP foci, on the other hand, the PCNA labelling
expanded to the upper layer (Figures 3A and 3B) and the labelling
index (49.3 ± 15.4%) was significantly higher than that of
colorectal normal mucosa without BGP expression (34.8 ±12.6%)
(P < 0.001) (Figure 4). PCNA labelling index of the colorectal
carcinoma was 60.1 ±8.6%. 
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transitional mucosa of ‘de novo’ carcinoma 
K-ras mutation in codon 12 was not detected in any of the speci-
mens including carcinoma, BGP foci and BGP negative colorectal
mucosa. On the other hand, p53 mutation was detected in 8 out 
of 17 (47.1%) in the carcinomas expressing p53 protein.
Interestingly, in spite of no p53 overexpression in the BGP foci,
there were frequent mutations in these foci. 7 out of 17 foci
(41.2%) had the p53 point mutations. There was no mutation in the
BGP negative mucosa adjacent to the carcinoma. In the carci-
nomas, the mutations existed in exon 5 (4 cases), exon 7 (2 cases),
and exon 8 (2 cases). In the BGP foci, the mutations were detected
in exon 5 (4 cases), exon 6 (1 case), exon 7 (1 case) and exon 8 
(1 case) (Table 1). The mutations of p53 in carcinoma and BGP
foci corresponded in three cases (cases 3, 12 and 15).
Nevertheless, the mutation of one BGP focus was disconcordant
with the carcinoma (case 1), and in 3 BGP foci only (cases 2, 7 and
17) and in 4 carcinomas only (cases 5, 6, 8 and 16). Because of the
considerably small amount of mutated PCR products from the
microdissected BGP foci in which normal cells were supposed to
be contained, 4 of 7 mutated codons were not sequenced in the
BGP foci. In cases 3 and 17, missence mutations in exon 5, codon
148 (Asp to Asn) and in exon 7, codon 258 (Glu to Lys) were
detected, respectively. The missence and silent mutation in exon 6,
codon 189 (Ala to Thr) and 187 (Gly to Gly) was sequenced in
case 7. 
DISCUSSION 
Concerning the carcinogenesis of sporadic colorectal carcinoma,
attention has been focused on another pathway, i.e. ‘de novo’
carcinogenesis (Shamsuddin et al, 1985; Shimoda et al, 1989;
Rembacken et al, 2000). A fair number of the colonic carcinomas
are assumed to arise directly from colonic mucosa unlike ex-
adenoma. If these assumptions are correct, it would be natural to
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Figure 1 Immunohistochemical staining of colonic carcinoma and the
transitional mucosa with anti-brain-type glycogen phosphorylase (BGP)
antibody (A) and anti-p53 antibody (B). Positive reactivity of BGP was
observed in the cytoplasm of carcinoma and the transitional mucosa (A). p53
protein accumulation was observed in the nuclei of the carcinoma, but not in
the BGP positive mucosa (B). (C) Haematoxylin-eosin staining. Magnification
153
A
B
Figure 2 Mesoscopical demonstration of a BGP stained section which
contains both carcinoma and BGP positive foci (A) (magnification 43 ).
Higher magnification of a single BGP positive focus which is marked in A (B)
(magnification 353) BGP foci in ‘de novo’ carcinogenesis 1501
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Figure 3 Immunohistochemical analyses of colonic mucosa adjacent to carcinoma with anti-BGP antibody (A and C) and anti-PCNA Ab (B and D). The
positive BGP staining was observed in these colonic tubules (A) (BGP focus). The PCNA labelling expanded to the upper layer in these colonic tubules of BGP
focus. (Magnification 503)consider that there are considerable reserve foci undergoing
genetic alterations towards malignant transformation in the macro-
scopically normal-looking mucosa bearing a carcinoma, since no
dysplastic change different from adenoma in the ACS has been
reported yet. In the present study, multifocal expression of the
BGP was observed in the colorectal mucosa adjacent to ‘de novo’
carcinoma. The BGP foci may be involved in the ‘transitional
mucosa’ (Filipe and Cooke, 1974) as mentioned earlier, because
the similar histologic characteristics to transitional mucosa such as
crypt distortion and basal cell hyperplasia were observed in the
BGP foci. The sites of BGP expression in tubules usually localized
in the generative zone, where a carcinoma is supposed to arise
from (Ming et al, 1967; Nagayo, 1975; Oohara et al, 1982;
Shimada et al, 1984, 1992; Matsuzaki et al, 1998). The expression
of BGP during ACS has recently shown excellent correlation with
the increased atypism and was found prior to p53 expression
(Tashima et al, 2000). These findings indicate that the expression
of BGP may be the phenotypic abnormality that precedes de-
finite morphological changes of neoplasm. It is therefore im-
portant to elucidate the genetic changes occurring in these
interesting foci. 
It has been suggested that genetic alterations of ‘de novo’
colorectal carcinoma is involved in infrequent K-ras mutation in
the carcinogenesis (Minamoto et al, 1994; Yamagata et al, 1994).
Aberrant crypt foci have been advocated as one putative preneo-
plastic lesion of the ‘de novo’ colorectal carcinoma without
macroscopic morphological changes (Bird, 1987; Pretlow et al,
1991, 1993; Shivapurkar et al, 1997). However, these foci may not
be related to the carcinogenesis of ‘de novo’ carcinoma, since
those include frequent K-ras mutation in codon 12 (Pretlow et al,
1993). The present study clearly showed that there was no codon
12 of K-ras mutation in the carcinomas without any adenoma
component, otherwise frequent p53 mutation was observed in the
carcinomas. We investigated only the codon 12 of K-ras, since it
has been described that no mutation in the codon 13 is detected in
addition to infrequent mutation of codon 12 in the ‘de novo’ carci-
noma (Minamoto et al, 1994; Yamagata et al, 1994). Surprisingly,
although none of the overexpressions of p53 protein was observed
in the BGP positive foci, the p53 gene frequently (41.2%) mutated
despite no K-ras mutation in codon 12. Since the sensitivity of
SSCP is limited and influenced by the experimental condition, the
authors estimated the detectability of these mutations as about
80% based on the previous report (Jordanova et al, 1997). 
There have been many reports discussing the correlation
between p53 protein overexpression and the p53 mutation.
Although it is generally accepted that the protein and mutation
correspond in carcinomas, some have described the incorrespon-
dence between the two. For example, Dunn et al (1994) examined
the correlation between p53 mutation and antibody staining using
81 primary breast carcinomas, and p53 mutations were associated
with positive p53 protein staining in only 2 patients. Other re-
searchers also concluded that accumulation of p53 protein, as
detectable by immunohistochemistry, is not a reliable indicator for
p53 gene mutation in human breast cancer (Lohmann et al, 1993;
Lisboa et al, 1997). In the present study, only about half on the p53
protein-positive colorectal carcinomas showed p53 mutation.
Concerning precancerous lesions in the gastrointestinal tract, it has
been described that p53 mutation in the intestinal metaplasia,
which is regarded as a major precursor of intestinal-type gastric
carcinoma, has been considerably frequently observed, but the
overexpression of p53 protein is rarely detected in it (Shiao et al,
1994). 
Proliferative characterization of BGP foci was conducted using
PCNA labelling index and was compared with that of BGP-negative
mucosa. PCNA staining revealed that there was an expansion of
proliferative compartment in BGP foci and that these were signi-
ficantly higher in a proliferating state than colorectal mucosa
without BGP. The present study detected the p53 mutation
frequently in the BGP foci including generative cell zone, as
mentioned above. Both the markers of PCNA and p53 have been
considered to be crucial to the demonstration of cell proliferation
in the cell cycle phases (Baker et al, 1990; Fearon and Vogelstein,
1990; Hollstein et al, 1991; Brito et al, 1992; Greenblatt et al,
1994; Levine et al, 1994). These observations suggest that the
generative cells in the BGP foci may deviate from the differentia-
tion and be blocked from apoptotic cell death. Thus, these novel
foci with BGP probably contribute to the research of the carcino-
genesis on the ‘de novo’ colorectal carcinogenesis. 
Studies on very early preneoplastic lesions are essential for
understanding the exact details of the molecular mechanism of
colorectal carcinogenesis. BGP-positive foci might be such a
candidate, being potentially early preneoplastic lesions with no
apparent neoplastic morphological change. Since ‘de novo’ carci-
noma is thought to arise directly from normal colorectal mucosa
shortly after p53 and APC mutation, or p53 mutation alone (Aoki
et al, 1994; Umetani et al, 2000), further investigations are neces-
sary to determine the relationship between p53 and APC mutation
in the BGP foci. 
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Figure 4 Distribution of PCNA labelling index in colorectal carcinoma and
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13.T S  T1N0M0/I/A  +  +  wild  wild 
N(BGP+) +  –  wild  wild 
N(BGP–) –  –  wild  wild 
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NA = not available, T = tumour, N = normal mucosa, BGP = brain (fetal)-type glycogen phosphorylase, C = caecum, A = ascending colon, Tr = transverse colon,
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